IPP Bureau
Jubilant Pharmova announces voluntary prepayment of US$ 75 million term loan
By IPP Bureau - June 15, 2024
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
Moderna announces positive Phase 3 efficacy data for next generation COVID-19 vaccine
By IPP Bureau - June 14, 2024
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
USFDA approves expanded age indication for GSK’s RSV vaccine ‘Arexvy’
By IPP Bureau - June 14, 2024
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Farxiga approved in the US for the treatment of paediatric type-2 diabetes
By IPP Bureau - June 14, 2024
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
AxoSim appoints Alif Saleh as CEO
By IPP Bureau - June 14, 2024
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Suven to acquire a majority stake in CDMO player ‘Sapala Organics’
By IPP Bureau - June 14, 2024
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Zydus receives USFDA’s tentative approval for Azilsartan Medoxomil and Chlorthalidone Tablets
By IPP Bureau - June 14, 2024
Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of US$ 77.9 mn in the United States (IQVIA MAT March 24).
Torrent Pharmaceuticals gets Form 483 with 5 observations for Indrad facility
By IPP Bureau - June 13, 2024
There was no observation related to data integrity reported
Pfizer updates on Phase 3 study of investigational gene therapy for ambulatory boys with Duchenne Muscular Dystrophy
By IPP Bureau - June 13, 2024
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Kardium announces US$ 104 million in new financing for innovative Atrial Fibrillation Treatment
By IPP Bureau - June 13, 2024
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Lilly's tirzepatide was superior to placebo for MASH resolution
By IPP Bureau - June 13, 2024
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release capsules
By IPP Bureau - June 12, 2024
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
IOL Chemicals receives EDQM CEP certificate for Pantoprazole Sodium Sesquihydrate and Allopurinol
By IPP Bureau - June 12, 2024
EDQM has also issued a Certificate of Suitability for Allopurino
Schneider Electric launches EcoStruxure for life science segment
By IPP Bureau - June 11, 2024
Accelerating sustainability in Indian pharma industry
